MOR MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab (CD38)and MOR210（C5aR1）.
MorphoSys will receive a 15% equity stake in HIBio and milestone payments across programs.$MorphoSys(MOR)$ $天境生物(IMAB)$
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
MOR MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab (CD38)and MOR210（C5aR1）.
MorphoSys will receive a 15% equity stake in HIBio and milestone payments across programs.$MorphoSys(MOR)$ $天境生物(IMAB)$